Floatz logo

Efaproxiral

Metastases

Spectrum Pharmaceuticals, IncSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

171 Active assets in the Metastases cohort.

Asset / SponsorPhaseRating
Eloxatin
Ruijin Hospital
Phase 4BBB
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

Efaproxiral is also rated in:

lung cancerDormant
B
Indicative ·
56 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
52 / 100
View asset →
central nervous system neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →